Heidelberg Pharma AG

👍 We had a great time in Frankfurt and had many interesting talks in which we could present our unique ADC technology.  👍

📢 2 Weeks to Go! Make sure to join the #HeidelbergPharma team at the 66th American Society of Hematology (#ASH) Annual Meeting in San Diego, from the 7-10 December!   Don’t miss key opinion leader in the field of #myeloma, Robert Orlowski, MD, PhD, who will present the latest clinical data from Heidelberg Pharma AG's ongoing Phase I/IIa trial with lead #ATAC candidate, HDP-101, targeting relapsed or refractory multiple myeloma, including a notable complete remission in one heavily pre-treated patient.   Session Details: 🔢 Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II 📅 Date: 8 December 2024 🕘 Time: 6:00 – 8:00 pm PST 👉 Location: Hall G–H   For more insights on HDP-101 and its potential, watch our latest R&D webinar with CMO Andras Strassz, MD, MBA, and leading KOLs here: https://lnkd.in/etQ4RBGT

⚡ Don't miss Heidelberg Pharma AG at this year's 66th American Society of Hematology (ASH) Annual Meeting, being held in San Diego, California from 7-10 December, where Robert Z. Orlowski, MD, PhD, principal investigator of the clinical study with lead candidate, HDP-101, will report the latest developments. ⚡ In the ongoing Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma one patient from the fifth cohort, who had been heavily pre-treated and received multiple courses of HDP-101, showed complete remission.   Presentation details: 📢Presenter: Robert Z. Orlowski, MD, PhD, Director of Myeloma, MD Anderson Cancer Center, Houston, Texas, USA 📌 Title: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma 🔢 Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II 📅 Date: 8 December 2024 🕘 Time: 6:00 – 8:00 pm PST 👉 Location: Hall G–H   Also watch #HeidelbergPharma's latest R&D webinar, featuring CMO, Andras Strassz, MD, MBA and Key Opinion Leaders in the field of myeloma as they discuss the progress of HDP-101 to date, here: https://lnkd.in/etQ4RBGT   #ADC #ATAC #ASH2024 #MultipleMyeloma

📣 Auch in diesem Jahr wird Heidelberg Pharma AG beim #DeutschesEigenkapitalforum in Frankfurt dabei sein und das Unternehmen mit seinen neuartigen ADC-Technologien, die Pionierarbeit für eine gezielte und hochwirksame Behandlung von Krebs leisten, präsentieren. 📣 Finanzvorstand Walter Miller stellt am 26. November um 11:15 Uhr unter dem Titel „The leader in next generation ADC payloads“ Heidelberg Pharmas ADC-Toolbox vor. Sie adressiert verschiedene Krebsarten mit unterschiedlichen Antikörper-Payload-Kombinationen und überwindet Tumorresistenzen, indem sie auch ruhende Tumorzellen abtötet. 🎯 Buchen Sie einen Termin mit Walter Miller und erfahren Sie mehr über Heidelberg Pharmas vielversprechenden Therapieansatz. #ADC #ATAC ##DeutschesEigenkapitalforum #EKF24 

♂ This November, Heidelberg Pharma AG proudly joins the Movember movement to raise awareness and support for men’s health, with a special focus on #ProstateCancer. ♂ Prostate cancer remains the most common cancer in men, and cases are expected to nearly double by 2040. At #HeidelbergPharma, we are committed to developing an innovative therapy for those facing this disease, with our preclinical candidate HDP-103, an Amanitin-based PSMA-ADC designed specifically for metastatic castration-resistant prostate cancer. #ADC #ATAC #Movember #ProstateCancerAwareness 

📢We are happy to announce that promising new clinical data on our lead ADC-candidate HDP-101 will be presented at the ASH Annual Meeting 2024 at the beginning of December in San Diego. 📢 Robert Z. Orlowski, MD, PhD, principal investigator at MD Anderson Cancer Center, Houston, Texas, USA, will report the latest developments from Heidelberg Pharma AG´s ongoing Phase I/IIa study of HDP-101 for the treatment of relapsed or refractory multiple myeloma.   🎤He will present a poster about “The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma” on 8 December, from 6 to 8 pm PST.   📌For more information see: https://lnkd.in/eWnaXZtX Heidelberg Pharma discussed the progress of its dose escalation study of HDP-101 recently in an R&D webinar. 🎥 The recording of the R&D webinar can be found here: https://lnkd.in/etQ4RBGT #ADC #ATAC #CancerResearch

📢 Today Anikó Pálfi will make the start with Heidelberg Pharma AG´s presentations at the World ADC San Diego 2024 ! 📢 🎤 Anikó Pálfi, Director Biochemistry & Cell Biology, will talk about “Leveraging 17p Deletion as a Biomarker & Patient Selection Tool for Amanitin Payload ADCs” on 4 November 2024, at 10:30 am PST. 🎤 Our CEO, Andreas Pahl, will present “HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors” on 6 November 2004, at 12:00 pm PST. 🎤 Torsten Hechler, Senior Vice President ADC Research, will elaborate on “ATACs: A New Payload Provides New Options for Cancer Therapy” on 6 November 2024, at 4:00 pm PST. #ADC #ATAC #CancerResearch

📢 We are happy to announce that Heidelberg Pharma AG will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November. 📢 At the World ADC San Diego 2024 we will several presentations. 🎤 Anikó Pálfi, Director Biochemistry & Cell Biology, will talk about “Leveraging 17p Deletion as a Biomarker & Patient Selection Tool for Amanitin Payload ADCs” on 4 November 2024, at 10:30 am PST. 🎤 Our CEO, Andreas Pahl, will present “HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors” on 6 November 2004, at 12:00 pm PST. 🎤 Torsten Hechler, Senior Vice President ADC Research, will elaborate on “ATACs: A New Payload Provides New Options for Cancer Therapy” on 6 November 2024, at 4:00 pm PST. 🎤 Heidelberg Pharma´s Chief Financial Officer, Walter Miller, will hold a company presentation at the "Deutsches Eigenkapitalforum" on 26 November in Frankfurt. For more detailed information click here: https://lnkd.in/eTykaXX4   #ADC #ATAC #CancerResearch

A major step achieved! Congratulations 🎉We look forward to continuing our successful cooperation!

🎞 Did you miss our R&D webinar featuring new clinical data presented at #IMS2024? 🎞 Catch up on the latest insights on Heidelberg Pharma AG´s lead #ATAC candidate, HDP-101, from our CMO, Andras Strassz, MD, MBA, and leading expert KOLs in the myeloma field, Shambavi Richard, MD, and Robert Orlowski, MD, PhD. 🎥 Watch here: https://lnkd.in/etQ4RBGT #ATAC #ADC #ClinicalUpdate #Webinar